Christian Récher

Research interests

Publications

• Long‐term follow‐up of VIALE‐A : Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia

  American Journal of Hematology · 2024 · 10.1002/ajh.27246

• Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia

  New England Journal of Medicine · 2022 · https://doi.org/10.1056/nejmoa2109965

• Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid Leukemia

  New England Journal of Medicine · 2022 · https://doi.org/10.1056/nejmoa2117344

• Eprenetapopt Plus Azacitidine in TP53 -Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)

  Journal of Clinical Oncology · 2021 · 10.1200/jco.20.02342

• Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

  Blood · 2020 · https://doi.org/10.1182/blood.2020007732

• Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1902688

• Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism

  Cancer Discovery · 2017 · https://doi.org/10.1158/2159-8290.cd-16-0441

• Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

  The Lancet Haematology · 2016 · 10.1016/s2352-3026(15)00247-1

• Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy

  Blood · 2016 · 10.1182/blood-2015-07-655860

• International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

  Blood · 2015 · https://doi.org/10.1182/blood-2015-01-621664

• Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition

  Blood · 2015 · 10.1182/blood-2015-01-621870

• MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study

  Blood · 2015 · 10.1182/blood-2015-05-647602

• Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials

  The Lancet Oncology · 2014 · https://doi.org/10.1016/s1470-2045(14)70281-5

• Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia

  Blood · 2013 · https://doi.org/10.1182/blood-2012-10-462879

• High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia

  Blood · 2012 · 10.1182/blood-2012-08-447367

• High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study

  Haematologica · 2011 · 10.3324/haematol.2011.047894

• Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial

  The Lancet · 2011 · 10.1016/s0140-6736(11)61040-4

• Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure

  Journal of Clinical Oncology · 2011 · 10.1200/jco.2011.35.8135

• Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice

  Journal of Clinical Investigation · 2010 · 10.1172/jci41495

• Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

  Blood · 2010 · 10.1182/blood-2010-06-289280

• Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience

  Blood · 2009 · https://doi.org/10.1182/blood-2009-07-233387

• High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis

  New England Journal of Medicine · 2007 · https://doi.org/10.1056/nejmoa070484

• Antileukemic activity of rapamycin in acute myeloid leukemia

  Blood · 2004 · 10.1182/blood-2004-06-2494

• Incidence and risk factors for central nervous system occurrencein elderly patients with diffuse large-B-cell lymphoma: influenceof rituximab

  Annals of Oncology · 2003 · 10.1093/annonc/mdh013

• Improved survival in cancer patients requiring mechanical ventilatory support: Impact of noninvasive mechanical ventilatory support

  Critical Care Medicine · 2001 · https://doi.org/10.1097/00003246-200103000-00009

Current projects

No projects listed.